DDW 2025 is the place to learn about TissueCypher and Barrett’s esophagus risk stratification
Data from two new TissueCypher studies will be presented at Digestive Disease Week 2025 in San Diego, CA.
If you’re planning to attend, book some time with our team to discuss how this innovative prognostic test can improve management of Barrett’s esophagus patients. The Castle Biosciences team will be at Booth 1017 near Registration.
Events featuring TissueCypher
DDW Product Theater
The Time is Now:
A Clinical Practice Model to Help Prevent Progression from
Barrett's to EAC
Sun., May 4, 2:45 - 3:30 p.m. PT
Add to calendar (.ics)
DDW Theater 1
Come hear best practices from a physician panel convened by EndoscopyNow to develop a clinical practice model that leverages TissueCypher to risk stratify Barrett's esophagus patients and avoid progression to esophageal adenocarcinoma.

Vivek Kaul, MD
Professor of Medicine,
Gastroenterology and Hepatology
University of Rochester Medical Center

Harshit Khara, MD
Interventional Gastroenterologist, Associate Professor of Medicine, Director of Endoscopy, Geisinger Medical Center

Jennifer Kolb, MD, MS
Assistant Professor of Medicine
Vatche and Tamar Manoukian Division of Digestive Diseases
David Geffen School of Medicine at UCLA
VA Greater Los Angeles Healthcare System

Sri Komanduri, MD, MS
Associate Chief,
Division of Gastroenterology and Hepatology; Professor of Medicine and Surgery
Division of Gastroenterology and Hepatology; Northwestern Feinberg School of Medicine
AGA Research Forum
Advances in Screening and Risk Stratification in Barrett's Esophagus
Session Number: 5270
TissueCypher Presentation:
Clinical utility of tissue systems pathology (TSP-9) risk stratification in patients with and without a family history of Barrett's esophagus and/or esophageal cancer
Presenter:
Mimi Canto, MD, MHS
Johns Hopkins School of Medicine
Tues., May 6, 10:00 a.m. PT
Add to calendar (.ics)
San Diego Convention Center
Sun., May 4, 12:30 - 1:30 p.m. PT
Add to calendar (.ics)
The tissue systems pathology test detected presence of missed neoplasia in a patient with non-dysplastic Barrett's esophagus

The tissue systems pathology test provides risk stratification for patients with Barrett's esophagus

Think BEyond the "Wait and See" paradigm for non-dysplastic
Barrett's esophagus

Dan Lister, MD, FACS
President and CoFounder of the AFS
Director of the Arkansas Heartburn Treatment Center
Sat., May 3, 11:30 a.m. - 12:00 p.m. PT
Add to calendar (.ics)
The tissue systems pathology test detected presence of missed neoplasia in a patient with non-dysplastic
Barrett's esophagus

Philip Woodworth, MD
Sky Ridge Heartburn and Reflux Treatment Center
Institute of Esophageal and Reflux Surgery
Mon., May 5, 12:15 - 12:45 p.m. PT
Add to calendar (.ics)

Castle Biosciences will have Area Managers, Medical Science Liaisons, product specialists and others available to answer any question you may have.
Sun., May 4 - Tues., May 6